These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 27993720

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC, Pan SL, Chao SW, Liu SP, Hsu JL, Yang YC, Li TK, Huang WJ, Guh JH.
    Biochem Pharmacol; 2014 Aug 01; 90(3):320-30. PubMed ID: 24915421
    [Abstract] [Full Text] [Related]

  • 3. Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.
    Voorhees PM, Gasparetto C, Moore DT, Winans D, Orlowski RZ, Hurd DD.
    Clin Lymphoma Myeloma Leuk; 2017 Jul 01; 17(7):424-432. PubMed ID: 28655599
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS, Jung KA, Kim SM, Hong YS, Ryu MH, Jang SJ, Moon DH, Cho DH, Kim JC, Lee JS, Kim TW.
    Cancer Chemother Pharmacol; 2011 Aug 01; 68(2):389-98. PubMed ID: 21046105
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
    Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G, Gemmill RM, Drabkin HA, Lloyd GK, Neuteboom ST, McConkey DJ, Palladino MA, Spear MA.
    Invest New Drugs; 2012 Dec 01; 30(6):2303-17. PubMed ID: 22080430
    [Abstract] [Full Text] [Related]

  • 8. Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
    Kiliccioglu I, Konac E, Varol N, Gurocak S, Yucel Bilen C.
    Genet Mol Res; 2014 May 09; 13(2):3721-31. PubMed ID: 24854658
    [Abstract] [Full Text] [Related]

  • 9. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
    Lee JK, Ryu JK, Yang KY, Woo SM, Park JK, Yoon WJ, Lee SH, Jeong KS, Kim YT, Yoon YB.
    Pancreas; 2011 Aug 09; 40(6):966-73. PubMed ID: 21487323
    [Abstract] [Full Text] [Related]

  • 10. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA, Sanchez E, Steinberg J, Shalitin D, Li ZW, Chen H, Berenson JR.
    Eur J Haematol; 2010 Mar 09; 84(3):201-11. PubMed ID: 19929977
    [Abstract] [Full Text] [Related]

  • 11. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
    Hideshima T, Qi J, Paranal RM, Tang W, Greenberg E, West N, Colling ME, Estiu G, Mazitschek R, Perry JA, Ohguchi H, Cottini F, Mimura N, Görgün G, Tai YT, Richardson PG, Carrasco RD, Wiest O, Schreiber SL, Anderson KC, Bradner JE.
    Proc Natl Acad Sci U S A; 2016 Nov 15; 113(46):13162-13167. PubMed ID: 27799547
    [Abstract] [Full Text] [Related]

  • 12. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L, Benedetti V, De Cesare M, Corna E, Cincinelli R, Zaffaroni N, Zunino F, Perego P.
    J Inorg Biochem; 2012 Aug 15; 113():94-101. PubMed ID: 22717676
    [Abstract] [Full Text] [Related]

  • 13. Supramolecular cisplatin-vorinostat nanodrug for overcoming drug resistance in cancer synergistic therapy.
    Xu S, Zhu X, Huang W, Zhou Y, Yan D.
    J Control Release; 2017 Nov 28; 266():36-46. PubMed ID: 28893609
    [Abstract] [Full Text] [Related]

  • 14. Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
    Sato A, Asano T, Ito K, Asano T.
    J Urol; 2012 Dec 28; 188(6):2410-8. PubMed ID: 23088964
    [Abstract] [Full Text] [Related]

  • 15. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y.
    J Cancer Res Clin Oncol; 2016 Feb 28; 142(2):379-87. PubMed ID: 26314218
    [Abstract] [Full Text] [Related]

  • 16. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
    Chen G, Xu Z, Chang G, Hou J, Hu L, Zhang Y, Yu D, Li B, Chang S, Xie Y, Zhang Y, Wei R, Wu H, Xiao W, Sun X, Tao Y, Gao L, Dai B, Shi J, Zhu W.
    Oncol Rep; 2017 Jul 28; 38(1):488-496. PubMed ID: 28560392
    [Abstract] [Full Text] [Related]

  • 17. Enhancing proteasome-lnhibitor effect by functionalized gold nanoparticles.
    Coelho SC, Rocha S, Pereira MC, Juzenas P, Coelho MA.
    J Biomed Nanotechnol; 2014 Apr 28; 10(4):717-23. PubMed ID: 24734524
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy.
    Urbinati G, Marsaud V, Plassat V, Fattal E, Lesieur S, Renoir JM.
    Int J Pharm; 2010 Sep 15; 397(1-2):184-93. PubMed ID: 20603204
    [Abstract] [Full Text] [Related]

  • 20. Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib.
    Korani M, Korani S, Zendehdel E, Jaafari MR, Sathyapalan T, Sahebkar A.
    Anticancer Agents Med Chem; 2020 Sep 15; 20(6):643-650. PubMed ID: 31985384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.